174 related articles for article (PubMed ID: 28205494)
1. Language Deficits as a Preclinical Window into Parkinson's Disease: Evidence from Asymptomatic Parkin and Dardarin Mutation Carriers.
García AM; Sedeño L; Trujillo N; Bocanegra Y; Gomez D; Pineda D; Villegas A; Muñoz E; Arias W; Ibáñez A
J Int Neuropsychol Soc; 2017 Feb; 23(2):150-158. PubMed ID: 28205494
[TBL] [Abstract][Full Text] [Related]
2. Syntax, action verbs, action semantics, and object semantics in Parkinson's disease: Dissociability, progression, and executive influences.
Bocanegra Y; García AM; Pineda D; Buriticá O; Villegas A; Lopera F; Gómez D; Gómez-Arias C; Cardona JF; Trujillo N; Ibáñez A
Cortex; 2015 Aug; 69():237-54. PubMed ID: 26103601
[TBL] [Abstract][Full Text] [Related]
3. High nigral iron deposition in LRRK2 and Parkin mutation carriers using R2* relaxometry.
Pyatigorskaya N; Sharman M; Corvol JC; Valabregue R; Yahia-Cherif L; Poupon F; Cormier-Dequaire F; Siebner H; Klebe S; Vidailhet M; Brice A; Lehéricy S
Mov Disord; 2015 Jul; 30(8):1077-84. PubMed ID: 26011561
[TBL] [Abstract][Full Text] [Related]
4. Neural correlates of executive functions in healthy G2019S LRRK2 mutation carriers.
Thaler A; Mirelman A; Helmich RC; van Nuenen BF; Rosenberg-Katz K; Gurevich T; Orr-Urtreger A; Marder K; Bressman S; Bloem BR; Giladi N; Hendler T;
Cortex; 2013 Oct; 49(9):2501-11. PubMed ID: 23357204
[TBL] [Abstract][Full Text] [Related]
5. Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers.
Brockmann K; Gröger A; Di Santo A; Liepelt I; Schulte C; Klose U; Maetzler W; Hauser AK; Hilker R; Gomez-Mancilla B; Berg D; Gasser T
Mov Disord; 2011 Nov; 26(13):2335-42. PubMed ID: 21989859
[TBL] [Abstract][Full Text] [Related]
6. DAT imaging and clinical biomarkers in relatives at genetic risk for LRRK2 R1441G Parkinson's disease.
Bergareche A; Rodríguez-Oroz MC; Estanga A; Gorostidi A; López de Munain A; Castillo-Triviño T; Ruiz-Martínez J; Mondragón E; Gaig C; Lomeña F; Sarasqueta C; Tolosa E; Martí-Massó JF
Mov Disord; 2016 Mar; 31(3):335-43. PubMed ID: 26686514
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and clinical features of LRRK2 mutations in patients with Parkinson's disease in southern Spain.
Gao L; Gómez-Garre P; Díaz-Corrales FJ; Carrillo F; Carballo M; Palomino A; Díaz-Martín J; Mejías R; Vime PJ; López-Barneo J; Mir P
Eur J Neurol; 2009 Aug; 16(8):957-60. PubMed ID: 19473361
[TBL] [Abstract][Full Text] [Related]
8. Neuropsychological Profile of Parkin Mutation Carriers with and without Parkinson Disease: The CORE-PD Study.
Caccappolo E; Alcalay RN; Mejia-Santana H; Tang MX; Rakitin B; Rosado L; Louis ED; Comella CL; Colcher A; Jennings D; Nance MA; Bressman S; Scott WK; Tanner CM; Mickel SF; Andrews HF; Waters C; Fahn S; Cote LJ; Frucht S; Ford B; Rezak M; Novak K; Friedman JH; Pfeiffer RF; Marsh L; Hiner B; Siderowf AD; Ross BM; Verbitsky M; Kisselev S; Ottman R; Clark LN; Marder KS
J Int Neuropsychol Soc; 2011 Jan; 17(1):91-100. PubMed ID: 21092386
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the genetic variability in Parkinson's disease from Southern Spain.
Bandrés-Ciga S; Mencacci NE; Durán R; Barrero FJ; Escamilla-Sevilla F; Morgan S; Hehir J; Vives F; Hardy J; Pittman AM
Neurobiol Aging; 2016 Jan; 37():210.e1-210.e5. PubMed ID: 26518746
[TBL] [Abstract][Full Text] [Related]
10. CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson's disease: a study in LRRK2 mutation carriers.
Majbour NK; Aasly JO; Hustad E; Thomas MA; Vaikath NN; Elkum N; van de Berg WDJ; Tokuda T; Mollenhauer B; Berendse HW; El-Agnaf OMA
Transl Neurodegener; 2020 May; 9(1):15. PubMed ID: 32375873
[TBL] [Abstract][Full Text] [Related]
11. Differentiating symptomatic Parkin mutations carriers from patients with idiopathic Parkinson's disease: contribution of automated segmentation neuroimaging method.
Bilgic B; Bayram A; Arslan AB; Hanagasi H; Dursun B; Gurvit H; Emre M; Lohmann E
Parkinsonism Relat Disord; 2012 Jun; 18(5):562-6. PubMed ID: 22445249
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Leucine-rich repeat kinase 2 (LRRK2) and Parkinson protein 2 (parkin, PARK2) genes mutations in Slovak Parkinson disease patients.
Bognar C; Baldovic M; Benetin J; Kadasi L; Zatkova A
Gen Physiol Biophys; 2013 Mar; 32(1):55-66. PubMed ID: 23531835
[TBL] [Abstract][Full Text] [Related]
13. Investigating Voice as a Biomarker for Leucine-Rich Repeat Kinase 2-Associated Parkinson's Disease.
Arora S; Visanji NP; Mestre TA; Tsanas A; AlDakheel A; Connolly BS; Gasca-Salas C; Kern DS; Jain J; Slow EJ; Faust-Socher A; Lang AE; Little MA; Marras C
J Parkinsons Dis; 2018; 8(4):503-510. PubMed ID: 30248062
[TBL] [Abstract][Full Text] [Related]
14. Olfactory deficits and cardiac 123I-MIBG in Parkinson's disease related to the LRRK2 R1441G and G2019S mutations.
Ruiz-Martínez J; Gorostidi A; Goyenechea E; Alzualde A; Poza JJ; Rodríguez F; Bergareche A; Moreno F; López de Munain A; Martí Massó JF
Mov Disord; 2011 Sep; 26(11):2026-31. PubMed ID: 21611983
[TBL] [Abstract][Full Text] [Related]
15. Intact working memory in non-manifesting LRRK2 carriers--an fMRI study.
Thaler A; Helmich RC; Or-Borichev A; van Nuenen BF; Shapira-Lichter I; Gurevich T; Orr-Urtreger A; Marder K; Bressman S; Bloem BR; Giladi N; Hendler T; Mirelman A;
Eur J Neurosci; 2016 Jan; 43(1):106-12. PubMed ID: 26536050
[TBL] [Abstract][Full Text] [Related]
16. Nigral and striatal connectivity alterations in asymptomatic LRRK2 mutation carriers: A magnetic resonance imaging study.
Vilas D; Segura B; Baggio HC; Pont-Sunyer C; Compta Y; Valldeoriola F; José Martí M; Quintana M; Bayés A; Hernández-Vara J; Calopa M; Aguilar M; Junqué C; Tolosa E;
Mov Disord; 2016 Dec; 31(12):1820-1828. PubMed ID: 27653520
[TBL] [Abstract][Full Text] [Related]
17. The impact of executive functions on verb production in patients with Parkinson's disease.
Colman KS; Koerts J; van Beilen M; Leenders KL; Post WJ; Bastiaanse R
Cortex; 2009 Sep; 45(8):930-42. PubMed ID: 19303593
[TBL] [Abstract][Full Text] [Related]
18. Resequencing analysis of five Mendelian genes and the top genes from genome-wide association studies in Parkinson's Disease.
Benitez BA; Davis AA; Jin SC; Ibanez L; Ortega-Cubero S; Pastor P; Choi J; Cooper B; Perlmutter JS; Cruchaga C
Mol Neurodegener; 2016 Apr; 11():29. PubMed ID: 27094865
[TBL] [Abstract][Full Text] [Related]
19. Quantitative analysis of language production in Parkinson's disease using a cued sentence generation task.
Vanhoutte S; De Letter M; Corthals P; Van Borsel J; Santens P
Clin Linguist Phon; 2012 Oct; 26(10):863-81. PubMed ID: 22954366
[TBL] [Abstract][Full Text] [Related]
20. Responsiveness to distracting stimuli, though increased in Parkinson's disease, is decreased in asymptomatic PINK1 and Parkin mutation carriers.
Verleger R; Hagenah J; Weiss M; Ewers T; Heberlein I; Pramstaller PP; Siebner HR; Klein C
Neuropsychologia; 2010 Jan; 48(2):467-76. PubMed ID: 19822161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
